Associate Professor Luke Selth

Associate Professor Luke Selth is a Cancer Council SA Beat Cancer Principal Research Fellow in the Flinders Health and Medical Research Institute (FHMRI) at Flinders University, where he directs the Prostate Cancer Research Group.

Prostate cancer will affect approximately one in seven men and causes more than 3,200 deaths each year in Australia. To improve outcomes for men with this disease, the Prostate Cancer Research Group at Flinders University undertakes basic research to characterise the mechanisms by which prostate tumours metastasise and become resistant to targeted therapies. We feed this new knowledge into translational research projects aimed at developing new drugs and biomarkers to improve the treatment and management of patients.

The Prostate Cancer Research Group collaborates widely with prostate cancer consumer advocates, other scientists, clinicians, computational biologists and engineers – in Australia and around the world – to ensure that our findings have maximal impact. Importantly, our “team science” approach means that we also undertake impactful research on other types of cancer, most notably breast cancer.

A/Prof Selth is a member of the Freemasons Centre for Male Health and Wellbeing and sits on the Scientific Advisory Committee for the South Australian Genomics Centre. He has received Young Investigator Awards from the Prostate Cancer Foundation of Australia and the Prostate Cancer Foundation, as well as funding from NHMRC, Cancer Australia, Cancer Council SA, Cancer Council NSW, the Flinders Foundation, Movember and The Hospital Research Foundation. He is a member of the editorial boards of Endocrine-Related Cancer, the flagship cancer journal for the Society of Endocrinology, and Cancer Research Communications, a major journal from the American Association of Cancer Research. His team’s research is regularly published in prominent journals including recent papers in Cancer Research, European Urology, Science Translational Medicine, Nature Cell Biology, Nature Medicine and Cancer Discovery.

‍